Spinocerebellar Ataxia Type 7 Overview

Save information for later
Sign Up

Learn About Spinocerebellar Ataxia Type 7

View Main Condition: Movement Disorders

What is the definition of Spinocerebellar Ataxia Type 7?
Spinocerebellar ataxia 7 (SCA7) is an inherited disease of the central nervous system that leads to impairment of specific nerve fibers carrying messages to and from the brain, resulting in degeneration of the cerebellum (the coordination center of the brain). SCA7 differs from most other forms of SCA in that visual problems, rather than poor coordination, are generally the earliest signs of the disease. Affected individuals have progressive changes in vision (which can result in blindness); symptoms of ataxia; slow eye movements; and mild changes in sensation or reflexes. Later symptoms include loss of motor control, unclear speech (dysarthria), and difficulty swallowing (dysphagia). SCA7 is caused by genetic changes in the ATXN7 gene and is inherited in an autosomal dominant manner.
What are the alternative names for Spinocerebellar Ataxia Type 7?
  • Spinocerebellar ataxia 7
  • ADCA, TYPE II
  • Autosomal dominant cerebellar ataxia type 2
  • OPCA III
  • OPCA with macular degeneration and external ophthalmoplegia
  • OPCA with retinal degeneration
  • OPCA3
  • Olivopontocerebellar atrophy 3
  • SCA7
  • Spinocerebellar ataxia type 7
Who are the top Spinocerebellar Ataxia Type 7 Local Doctors?
Elite in Spinocerebellar Ataxia Type 7
Victor Galvez
Elite in Spinocerebellar Ataxia Type 7
Victor Galvez
Mexico, MEX, MX 

Victor Galvez practices in Mexico, Mexico. Mr. Galvez is rated as an Elite expert by MediFind in the treatment of Spinocerebellar Ataxia Type 7. His top areas of expertise are Spinocerebellar Ataxia Type 7, Olivopontocerebellar Atrophy, Spinocerebellar Ataxia, and Spinocerebellar Ataxia Type 2.

Elite in Spinocerebellar Ataxia Type 7
Rosalinda Diaz
Elite in Spinocerebellar Ataxia Type 7
Rosalinda Diaz
Mexico City, DIF, MX 

Rosalinda Diaz practices in Mexico City, Mexico. Ms. Diaz is rated as an Elite expert by MediFind in the treatment of Spinocerebellar Ataxia Type 7. Her top areas of expertise are Spinocerebellar Ataxia Type 7, Olivopontocerebellar Atrophy, Spinocerebellar Ataxia, and Spinocerebellar Ataxia Type 5.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Spinocerebellar Ataxia Type 7
Jonathan J. Magana
Elite in Spinocerebellar Ataxia Type 7
Jonathan J. Magana
México Xochimilco No. 289, C.P, 
Arenal, MEX, MX 

Jonathan Magana practices in Arenal, Mexico. Mr. Magana is rated as an Elite expert by MediFind in the treatment of Spinocerebellar Ataxia Type 7. His top areas of expertise are Spinocerebellar Ataxia Type 7, Olivopontocerebellar Atrophy, Spinocerebellar Ataxia Type 5, and Spinocerebellar Ataxia Type 4.

View All Doctors
What are the latest Spinocerebellar Ataxia Type 7 Clinical Trials?
Natural History of Spinocerebellar Ataxia Type 7 (SCA7)
Natural History of Spinocerebellar Ataxia Type 7 (SCA7)
Enrollment Status: Recruiting
Publish Date: September 30, 2025

Background: Spinocerebellar ataxia type 7 (SCA7) is a disease in which people have problems with coordination, balance, speech and vision. It is caused by a change in the ATXN7 gene. A mutation in this ATXN7 gene causes changes in eye cells, which can lead to vision loss. There is no cure for SCA7 but researchers are looking for possible treatments. Researchers need more information about SCA7. They want to c...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Riluzole in Patients With Spinocerebellar Ataxia Type 7: a Randomized , Double-blind, Placebo-controlled Pilot Trial With a Lead in Phase
Riluzole in Patients With Spinocerebellar Ataxia Type 7: a Randomized , Double-blind, Placebo-controlled Pilot Trial With a Lead in Phase
Who is this study for: Patients with spinocerebellar ataxia type 7
Enrollment Status: Recruiting
Publish Date: December 02, 2024
Intervention Type: Drug
Study Drug: Riluzole
Study Phase: Phase 2/Phase 3

Summary: Spinocerebellar ataxia type 7 (SCA7) belongs to the dominant forms of inherited cerebellar ataxias (CA), being one of the rarest form. SCA7 has no therapeutic options, so that the relentless course, the important visual deficit that accompanies CA, and the possibility of disease development in childhood are pressing unmet needs. The investigators published encouraging data on riluzole in inherited...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center